Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study ; volume:8 ; number:1 ; day:5 ; month:11 ; year:2022 ; pages:1-8 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (5.11.2022), 1-8, 12.2022
- Urheber
-
Rugo, Hope S.
Kabos, Peter
Beck, J. Thad
Jerusalem, Guy
Wildiers, Hans
Sevillano, Elena
Paz-Ares, Luis
Chisamore, Michael J.
Chapman, Sonya C.
Hossain, Anwar M.
Chen, Yanyun
Tolaney, Sara M.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00482-2
- URN
-
urn:nbn:de:101:1-2023012022061154432002
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:25 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rugo, Hope S.
- Kabos, Peter
- Beck, J. Thad
- Jerusalem, Guy
- Wildiers, Hans
- Sevillano, Elena
- Paz-Ares, Luis
- Chisamore, Michael J.
- Chapman, Sonya C.
- Hossain, Anwar M.
- Chen, Yanyun
- Tolaney, Sara M.
- SpringerLink (Online service)
Ähnliche Objekte (12)
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
Objective Responses in Metastatic Pleomorphic Rhabdomyosarcoma Treated with Combination of Doxorubicin and Pembrolizumab: A Case Series
Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study
Pembrolizumab as first-line treatment for metastatic uveal melanoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
Eribulin plus carboplatin combination for HER2-negative metastatic breast cancer: a multicenter, real-world cohort study
Pembrolizumab
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab